Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ: MDGL · IEX Real-Time Price · USD
267.04
+8.23 (3.18%)
At close: Mar 28, 2024, 4:00 PM
268.21
+1.17 (0.44%)
After-hours: Mar 28, 2024, 7:59 PM EDT

Madrigal Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 2023202220212020201920182017201620152014 2013 - 2004
Selling, General & Admin
108.1548.1337.3221.8622.6515.297.679.290.8115.75
Upgrade
Research & Development
272.35245.44205.16184.8172.3225.3924.3915.932.4368.21
Upgrade
Operating Expenses
380.5293.57242.48206.6794.9740.6832.0625.223.2383.95
Upgrade
Operating Income
-380.5-293.57-242.48-206.67-94.97-40.68-32.06-25.22-3.23-83.95
Upgrade
Interest Expense / Income
12.713.96000001.213.612.21
Upgrade
Other Expense / Income
-19.58-2.19-0.64-4.43-11.02-7.87-0.91-0.05--
Upgrade
Pretax Income
-373.63-295.35-241.85-202.24-83.95-32.81-31.15-26.39-6.84-86.16
Upgrade
Net Income
-373.63-295.35-241.85-202.24-83.95-32.81-31.15-26.39-6.84-86.16
Upgrade
Shares Outstanding (Basic)
19171715151512503
Upgrade
Shares Outstanding (Diluted)
19171715151512503
Upgrade
Shares Change
9.05%3.64%7.05%0.34%4.04%20.84%135.27%2943.44%-93.92%38.76%
Upgrade
EPS (Basic)
-19.99-17.23-14.63-13.09-5.45-2.22-2.54-5.07-40.03-30.45
Upgrade
EPS (Diluted)
-19.99-17.23-14.63-13.09-5.45-2.22-2.54-5.07-40.03-30.45
Upgrade
Free Cash Flow
-325.71-225.07-184.13-157.9-41.8-25.53-22.44-16.91-3.14-79.07
Upgrade
Free Cash Flow Per Share
-17.43-13.13-11.13-10.22-2.71-1.73-1.83-3.25-18.37-28.10
Upgrade
EBITDA
-360.39-290.92-241.44-201.77-83.84-32.72-31.08-25.18-3.23-83.28
Upgrade
Depreciation & Amortization
0.530.470.410.470.110.10.08000.67
Upgrade
EBIT
-360.92-291.39-241.85-202.24-83.95-32.81-31.15-25.18-3.23-83.95
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).